C17orf49

Across TCGA pan-cancer cohorts, C17orf49 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C17orf49 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher C17orf49 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C17orf49 expression acts as an unfavorable survival marker.

SARC and ESCA are the cancer types where C17orf49 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

C17orf49–SARC (DFS)

Open the SARC breakdown →